All In Biotech

Drug Trial Radar · NCT05842954

Efficacy, Safety and Tolerability of KLU156 in Adults and Children With Uncomplicated P. Falciparum Malaria

A Randomized, Open-label, Multicenter Study to Compare Efficacy, Safety and Tolerability of KLU156 With Coartem® in the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Adults and Children Followed by an Extension Phase With Repeated KLU156 Treatment

Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,720 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,720

Actual

Start

Mar 7, 2024

Primary completion

Jun 27, 2025

Study completion Nov 25, 2025

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
Collaborators
Medicines for Malaria Venture (MMV), EDCTP, WANECAM
First posted
May 6, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 2 months, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aimed to confirm the efficacy, safety and tolerability of KLU156, a fixed dose combination of ganaplacide (KAF156) and a solid dispersion formulation of lumefantrine (lumefantrine-SDF), when administered once daily for three days in adults and children ≥ 10 kg of body weight suffering from uncomplicated P. falciparum malaria (with or without other Plasmodium spp. co-infection). In the extension phase, the safety, tolerability and efficacy of repeated treatment with KLU156 was assessed for a maximum of approximately 18 months in patients who did not experience early treatment failure (ETF), who did not experience any study treatment-related SAE (Serious Adverse Event) previously and who gave informed consent to participate in the Extension phase.

Conditions

  • Uncomplicated Plasmodium Falciparum Malaria

Interventions

  • KLU156Drug

    Oral use. KLU156 (400/480 mg) was the dose for patients with a bodyweight ≥ 35kg. Patients \< 35kg took a fraction of the dose according to weight group as defined in the protocol.

  • CoartemDrug

    Oral use. Dosing was selected based on patient's body weight as per product's label.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Core Phase: PCR-corrected Adequate Clinical and Parasitological Response (ACPR) at Day 29Time frame: Day 29 (i.e., 28 days post-first dose administration)
  2. Core Phase: Uncorrected ACPR (US NDA Submission) at Day 29Time frame: Day 29

Locations

32 sites in 12 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Banfora, Burkina Faso

  • Novartis Investigative Site

    Bobo-Dioulasso, Burkina Faso

  • Novartis Investigative Site

    Nanoro, Burkina Faso

  • Novartis Investigative Site

    Ouagadougou, Burkina Faso

  • Novartis Investigative Site

    Sabou, Burkina Faso

  • Novartis Investigative Site

    Abidjan, Côte d’Ivoire

  • Novartis Investigative Site

    Agboville, Côte d’Ivoire

  • Novartis Investigative Site

    Azaguié, Côte d’Ivoire

  • Novartis Investigative Site

    Kimpese, Bas-Congo Province, Democratic Republic of the Congo

  • Novartis Investigative Site

    Kisantu, Bas-Congo Province, Democratic Republic of the Congo

  • Novartis Investigative Site

    Lubumbashi, Du Haut Katanga, Democratic Republic of the Congo

  • Novartis Investigative Site

    Kenge, Kwango, Democratic Republic of the Congo

  • Novartis Investigative Site

    Masi-Manimba, Kwilu, Democratic Republic of the Congo

  • Novartis Investigative Site

    Lambaréné, Gabon

  • Novartis Investigative Site

    Libreville, Gabon

  • Novartis Investigative Site

    Kintampo, Ghana

  • Novartis Investigative Site

    Navrango, Ghana

  • Novartis Investigative Site

    Kombewa, Kenya

  • Novartis Investigative Site

    Nairobi, Kenya

  • Novartis Investigative Site

    Siaya, Kenya

  • Novartis Investigative Site

    Sotouba, Mali

  • Novartis Investigative Site

    Niamey, Niger

  • Novartis Investigative Site

    Kigali, Rwanda

  • Novartis Investigative Site

    Rubavu, Rwanda

  • Novartis Investigative Site

    Rusizi, Rwanda

  • Novartis Investigative Site

    Gicumbi, Northern Province, Rwanda

  • Novartis Investigative Site

    Bagamoyo, Tanzania

  • Novartis Investigative Site

    Korogwe Tanga, Tanzania

  • Novartis Investigative Site

    Tanga, Tanzania

  • Novartis Investigative Site

    Tororo, Uganda

  • Novartis Investigative Site

    Ndola, Zambia

  • Novartis Investigative Site

    Nchelenge, Luapula Province, Zambia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.